A statement released earlier today by Needham about Neurocrine Biosciences (NYSE:NBIX) bumps the target price to $62.00
- Updated: October 18, 2016
In a report released on 10/18/2016 Needham increased the stock price target of Neurocrine Biosciences (NYSE:NBIX) to $62.00 indicating a possible upside of 0%.
Previously on Tuesday October 04, 2016, Leerink Swann reported on Neurocrine Biosciences (NYSE:NBIX) increased the target price from $0.00 to $70.00. At the time, this indicated a possible upside of 0.40%.
Yesterday Neurocrine Biosciences (NYSE:NBIX) traded 4.23% higher at $0.00. Neurocrine Biosciences’s 50-day moving average is $49.92 and its 200-day moving average is $47.80. The last closing price is down -7.75% from the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trading volume was down over the average, with 565,703 shares of NBIX changing hands under the typical 761,258
See Chart Below
Neurocrine Biosciences has a one year low of $31.25 and a one year high of $58.46 Neurocrine Biosciences’s total market value is presently $0.
A total of 8 analysts have released a research note on NBIX. Three analysts rating the company a strong buy, six analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $68.25.
More About Neurocrine Biosciences (NYSE:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.